- Home
- MBC vs NVAX Comparison
MBC vs NVAX Comparison
Compare MBC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- NVAX
- Stock Information
- Founded
- MBC 1954
- NVAX 1987
- Country
- MBC United States
- NVAX United States
- Employees
- MBC N/A
- NVAX N/A
- Industry
- MBC Agricultural Chemicals
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBC Industrials
- NVAX Health Care
- Exchange
- MBC Nasdaq
- NVAX Nasdaq
- Market Cap
- MBC 1.4B
- NVAX 1.3B
- IPO Year
- MBC N/A
- NVAX 1995
- Fundamental
- Price
- MBC $11.94
- NVAX $8.37
- Analyst Decision
- MBC Strong Buy
- NVAX Buy
- Analyst Count
- MBC 1
- NVAX 6
- Target Price
- MBC $15.00
- NVAX $15.33
- AVG Volume (30 Days)
- MBC 1.3M
- NVAX 7.1M
- Earning Date
- MBC 08-06-2025
- NVAX 08-06-2025
- Dividend Yield
- MBC N/A
- NVAX N/A
- EPS Growth
- MBC N/A
- NVAX N/A
- EPS
- MBC 0.72
- NVAX 2.54
- Revenue
- MBC $2,777,000,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- MBC N/A
- NVAX $52.02
- Revenue Next Year
- MBC $4.37
- NVAX N/A
- P/E Ratio
- MBC $16.54
- NVAX $3.29
- Revenue Growth
- MBC 4.05
- NVAX 9.22
- 52 Week Low
- MBC $9.63
- NVAX $5.01
- 52 Week High
- MBC $20.67
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- MBC 57.04
- NVAX 65.20
- Support Level
- MBC $10.76
- NVAX $6.36
- Resistance Level
- MBC $12.99
- NVAX $8.46
- Average True Range (ATR)
- MBC 0.45
- NVAX 0.53
- MACD
- MBC 0.04
- NVAX 0.14
- Stochastic Oscillator
- MBC 52.91
- NVAX 72.83
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.